Skip to main content

Verrica Pharmaceuticals Inc.

VRCA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001660334

In the last 90 days, Verrica Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $28.5M in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $210.9K in total
4
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +4 vs. previous quarter
43
13F valueReported value at the end of Q2 2026
$28.5M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding VRCA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding VRCA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Verrica Pharmaceuticals Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2026 (view filing)5:00 PM ETAug 171 dayZawitz DavidChief Operating OfficerPPurchase+6.00K$4.98+$29.9K+28.6%27.0K after
Aug 18, 2026 (view filing)5:00 PM ETAug 14-174 daysRieger JaysonCEO and PresidentPPurchase+25.0K$5.03+$125.8K+13.7%207.6K after2 lots
Aug 18, 2026 (view filing)5:00 PM ETAug 17-181 dayRosenberg Noah L.CMOPPurchase+6.23K$4.91+$30.6K+264.3%8.59K after2 lots
Aug 18, 2026 (view filing)5:00 PM ETAug 18Same dayKirby John J.Interim CFOPPurchase+5.00K$4.93+$24.6K+26.4%24.0K after
Nov 25, 2025 (view filing)Nov 25Same dayZawitz DavidChief Operating OfficerPPurchase+10.0K$4.24+$42.4K+90.9%21.0K after
Nov 25, 2025 (view filing)Nov 25Same dayZawitz DavidChief Operating OfficerPPurchase+2.50K–––2.50K afterDerivative
Nov 25, 2025 (view filing)Nov 25Same dayRieger JaysonCEO and PresidentPPurchase+94.3K$4.24+$399.9K+106.8%182.6K after
Nov 25, 2025 (view filing)Nov 25Same dayRieger JaysonCEO and PresidentPPurchase+23.6K–––23.6K afterDerivative
Nov 25, 2025 (view filing)Nov 25Same dayRosenberg Noah L.CMOPPurchase+2.36K$4.24+$9.99KNew position2.36K after
Nov 25, 2025 (view filing)Nov 25Same dayRosenberg Noah L.CMOPPurchase+589–––589 afterDerivative

Top 10 13F holders, Q2 2026

The largest institutional positions in Verrica Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 43 holders
Institutions holding VRCA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Caligan Partners LP923,910$5.65M0.27%00.0%Unchanged
Cannell Capital LLC783,923$4.80M3.35%+98,800+14.4%Added
Affinity Asset Advisors, LLC707,338$4.33M0.21%00.0%Unchanged
Velan Capital Investment Management LP471,559$2.89M1.77%00.0%Unchanged
Armistice Capital, LLC426,304$2.61M0.07%−91,877−17.7%Reduced
Boothbay Fund Management, LLC280,734$1.72M0.03%00.0%Unchanged
Vanguard Capital Management LLC279,310$1.71M0.00%+90,552+48.0%Added
Mariner, LLC207,230$1.27M0.00%+182,686+744.3%Added
Geode Capital Management, LLC138,160$845.7K0.00%−757−0.5%Reduced
BlackRock, Inc.74,344$455.0K0.00%+35,791+92.8%Added

Holders of 5% or more of VRCA

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Verrica Pharmaceuticals Inc..

See all 2 holders and filings
Largest holders of VRCA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Caligan Partners LP13G9.99%15.9M sharesNewFeb 12, 20251 filingFeb 12, 2025SEC
Armistice Capital, LLC13G/A9.99%9.24M shares0.00 ppfrom 9.99%Feb 14, 20252 filingsMay 15, 2025SEC